الفهرس 
Title : Non-invasive biomarkers for assessment of liver fibrosis in chronic hepatitis c patients before and after antiviral treatment
AbstractOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Liver fibrosis assessment after eradication of HCV is urgently required. This work was concerned with determining Cartilage Oligomeric Matrix Protein (COMP) levels in different hepatic fibrosis stages and estimating its performance in monitoring hepatic fibrosis. Methods: This study included 88 patients with different fibrosis stages who achieved a sustained virological response following direct-acting anti-virals. FibroScan and COMP were determined before and after one year from the end of treatment. Results: FibroScan showed that 16.7% and 5.3% of patients with F3 and F4, showed reversal of hepatic fibrosis. On the contrary, F1 and F2 patients showed no reversal of hepatic fibrosis. As well, 28.6%, 71.4%, 25% and 28.9% of patients with F1, F2, F3 and F4, respectively, showed regression of hepatic fibrosis. However, 57.1%, 14.3%, 50% and 65.8% of patients with F1, F2, F3 and F4 remained stationary. 41.7%, 14.3% , 14.3% and 3.8% of patients with F0, F1, F2 and F3, respectively, showed progression of hepatic-fibrosis. COMP levels increased with liver-fibrosis progression. COMP enabled correct identification of F2-F4, F3-F4 and F4 with areas under curve 0.77, 0.79 and 0.79, respectively. Our findings showed that 68.4%, 87.1% and 98.6% of F4, F3-F4 and F4, were positive for COMP. The COMP levels after treatment were not significantly changed (P > 0.05), especially in patients with F3 and F4 because more than 55% of the liver fibrosis had not changed and remained stationary. Conclusion: This work provides a promising non-invasive marker for assessment of liver fibrosis before and after treatment with direct antiviral drugs.